Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $71.91
  • 50 Day Moving Average: $73.69
  • 200 Day Moving Average: $77.47
  • 52-Week Range: $70.83 - $103.10
  • Trailing P/E Ratio: 6.67
  • Foreward P/E Ratio: 6.90
  • P/E Growth: -2.71
  • Market Cap: $95.03B
  • Outstanding Shares: 1,317,456,000
  • Beta: 1.2
Profitability:
  • Net Margins: 47.74%
  • Return on Equity: 100.57%
  • Return on Assets: 32.49%
Debt:
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.76%
Additional Links:
Companies Related to Gilead Sciences:

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 9 Hold Ratings, 18 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $96.80 (34.21% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetDetails
1/14/2017Jefferies GroupReiterated RatingBuy$93.00View Rating Details
1/13/2017BMO Capital MarketsReiterated RatingMarket Perform$88.00View Rating Details
1/13/2017Goldman Sachs Group Inc.Reiterated RatingHold$81.00View Rating Details
1/11/2017Stifel NicolausReiterated RatingBuy$100.00View Rating Details
1/6/2017Cowen and CompanyReiterated RatingBuy$100.00View Rating Details
1/3/2017RBC Capital MarketsReiterated RatingBuy$90.00View Rating Details
12/21/2016Robert W. BairdReiterated RatingOutperform$100.00View Rating Details
12/20/2016Credit Suisse Group AGSet Price TargetBuy$93.00View Rating Details
12/4/2016Piper Jaffray Cos.Reiterated RatingOverweight$102.00View Rating Details
11/15/2016Leerink SwannReiterated RatingMarket Perform$89.00View Rating Details
11/7/2016MizuhoInitiated CoverageBuy$88.00View Rating Details
11/6/2016Maxim GroupReiterated RatingHoldView Rating Details
11/4/2016Barclays PLCReiterated RatingOverweight$105.00View Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingOverweight$115.00 -> $101.00View Rating Details
11/2/2016Royal Bank Of CanadaLower Price TargetOutperform$95.00 -> $90.00View Rating Details
10/26/2016William BlairReiterated RatingOutperformView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00View Rating Details
9/25/2016Bank of America Corp.Reiterated RatingNeutral$100.00View Rating Details
9/23/2016GabelliReiterated RatingBuyView Rating Details
9/22/2016Berenberg BankInitiated CoverageBuyView Rating Details
9/6/2016Morgan StanleySet Price TargetHold$100.00View Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
7/26/2016Needham & Company LLCDowngradeBuy -> Hold$84.60 -> $88.55View Rating Details
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details
(Data available from 1/19/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017ListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
Current Year EPS Consensus Estimate: $11 EPS
Next Year EPS Consensus Estimate: $10.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.77$3.04$2.87
Q4 20163$1.14$2.76$2.12
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.61%
Payout Ratio:17.44% (Based on Trailing 12 Months of Earnings)
17.09% (Based on Current Year Consensus EPS Estimate)
17.99% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 73.46%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline
News IconTaking a Look at the Chart for Gilead Sciences Inc. (GILD) - The USA Commerce (NASDAQ:GILD)
theusacommerce.com - January 19 at 3:55 AM
News IconGilead Sciences (GILD) : Meeder Asset Management Inc Boosts Position by $5876223 (NASDAQ:GILD)
lasignare.com - January 18 at 5:53 PM
us.rd.yahoo.com logoGilead Sciences: What to Expect When You're Expecting Earnings (NASDAQ:GILD)
us.rd.yahoo.com - January 18 at 5:52 PM
investors.com logoGilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen (NASDAQ:GILD)
www.investors.com - January 18 at 5:52 PM
fool.com logoThese 3 Healthcare Stocks Are Ridiculously Cheap (NASDAQ:GILD)
www.fool.com - January 18 at 9:36 AM
nasdaq.com logoAgree To Buy Gilead Sciences At $55, Earn 4.4% Using Options (NASDAQ:GILD)
www.nasdaq.com - January 17 at 3:21 PM
forbes.com logoThe U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C (NASDAQ:GILD)
www.forbes.com - January 17 at 2:31 PM
istreetwire.com logoStocks Intraday Alert: Gilead Sciences Inc. (GILD), Mast Therapeutics, Inc. (MSTX), The Coca-Cola Company (KO) - iStreetWire (NASDAQ:GILD)
istreetwire.com - January 17 at 8:52 AM
News IconTop Gainers of the Day: Gilead Sciences Inc. (NASDAQ:GILD) from Biotechnology (NASDAQ:GILD)
twincountynews.com - January 15 at 10:08 PM
News IconThe Gilead Sciences (GILD) - Investment Analysts' Weekly Ratings Updates (NASDAQ:GILD)
latribunadecanarias.com - January 15 at 5:07 PM
News IconThe Key To HIV: Gilead Sciences, To Develop Drugs For HIV And NASH, Details Inside - iTech Post (NASDAQ:GILD)
www.itechpost.com - January 14 at 5:27 PM
fool.com logoDonald Trump Just Leveled Drug Companies With These 4 Words (NASDAQ:GILD)
www.fool.com - January 14 at 5:27 PM
fool.com logoShould Investors Bet on Gilead Sciences Version 3.0? (NASDAQ:GILD)
www.fool.com - January 14 at 12:30 PM
News IconGilead Sciences Inc. (NASDAQ:GILD) Assigned A Consensus Outperform Rating (NASDAQ:GILD)
seputarkita.info - January 13 at 11:28 PM
News IconGilead Sciences, Inc. (GILD) Given Buy Rating at Stifel Nicolaus (NASDAQ:GILD)
lasignare.com - January 13 at 11:28 PM
gurufocus.com logoRhenman & Partners Asset Management AB Buys Gilead Sciences Inc, Medtronic PLC, Pfizer Inc, Sells Shire PLC ... - GuruFocus.com (NASDAQ:GILD)
www.gurufocus.com - January 13 at 6:25 PM
istreetwire.com logoStocks on Trader's Radar: Mast Therapeutics, Inc. (MSTX), Gilead Sciences Inc. (GILD), The Charles Schwab ... - iStreetWire (NASDAQ:GILD)
istreetwire.com - January 13 at 6:25 PM
seekingalpha.com logoGilead Goal 2018 - Changing The Conversation - Seeking Alpha (NASDAQ:GILD)
seekingalpha.com - January 13 at 6:25 PM
News IconUpdate on Gilead Sciences Inc. (NASDAQ:GILD) for the day (NASDAQ:GILD)
twincountynews.com - January 13 at 1:19 AM
investopedia.com logoGilead To Focus on NASH and HIV Drugs In 2017 (GILD) (NASDAQ:GILD)
www.investopedia.com - January 12 at 8:19 PM
smarteranalyst.com logoThese Analysts Neutral On Gilead Sciences, Inc. (GILD) Following Sell Side Meeting (NASDAQ:GILD)
www.smarteranalyst.com - January 12 at 8:19 PM
istreetwire.com logoTrader's Buzzers: Whiting Petroleum Corporation (WLL), Gilead Sciences Inc. (GILD), AbbVie Inc. (ABBV) - iStreetWire (NASDAQ:GILD)
istreetwire.com - January 12 at 3:17 PM
finance.yahoo.com logoGilead (GILD) HBV Drug Vemlidy Receives European Approval (NASDAQ:GILD)
finance.yahoo.com - January 12 at 3:17 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock? (NASDAQ:GILD)
finance.yahoo.com - January 12 at 3:17 PM
finance.yahoo.com logoBiotech Short Sellers Run for Cover (NASDAQ:GILD)
finance.yahoo.com - January 12 at 3:17 PM
blogs.barrons.com logoGilead Sciences: Time for Some M&A Flexibility? (NASDAQ:GILD)
blogs.barrons.com - January 12 at 3:17 PM
investopedia.com logoGilead Sciences to Focus on NASH and HIV Drugs (NASDAQ:GILD)
www.investopedia.com - January 12 at 3:17 PM
investopedia.com logoGilead’s Hepatitis B Drug Vemlidy Approved In EU (NASDAQ:GILD)
www.investopedia.com - January 12 at 3:17 PM
smarteranalyst.com logoStock Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces Vemlidy Receives European Marketing Authorization (NASDAQ:GILD)
www.smarteranalyst.com - January 12 at 1:35 AM
seekingalpha.com logoGilead Sciences (GILD) at 35th Annual JPMorgan Healthcare Conference - Slideshow (NASDAQ:GILD)
seekingalpha.com - January 12 at 1:35 AM
us.rd.yahoo.com logoGilead Sciences: The M&A Question (NASDAQ:GILD)
us.rd.yahoo.com - January 12 at 1:35 AM
smarteranalyst.com logoStock Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces Vemlidy Receives European Marketing Authorization - Smarter Analyst (NASDAQ:GILD)
www.smarteranalyst.com - January 11 at 8:34 PM
uk.finance.yahoo.com logoEuropean Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection (NASDAQ:GILD)
uk.finance.yahoo.com - January 11 at 3:33 PM
News IconThis Stumbling Biotech Stock Still Has a Lot of Promise (NASDAQ:GILD)
portal.kiplinger.com - January 11 at 3:33 PM
forbes.com logoTrump's Comments Are Big Pharma's Nightmare (NASDAQ:GILD)
www.forbes.com - January 11 at 3:33 PM
finance.yahoo.com logoAndersen: Take Trump seriously, but not literally (NASDAQ:GILD)
finance.yahoo.com - January 11 at 3:33 PM
247wallst.com logoJefferies Has 5 Top Biotech Stocks to Buy for 2017 - 24/7 Wall St. (NASDAQ:GILD)
247wallst.com - January 10 at 9:50 PM
News IconGilead Sciences, Inc. (GILD) Shares Sold by LS Investment Advisors LLC (NASDAQ:GILD)
itapunta.com - January 10 at 4:49 PM
News IconHigh Market Cap Stock of the Day – Gilead Sciences Inc. (NASDAQ:GILD) (NASDAQ:GILD)
twincountynews.com - January 10 at 4:49 PM
News IconBiotechnology: Gilead Sciences Inc. (NASDAQ:GILD) Position of the day (NASDAQ:GILD)
baddgoddess.com - January 10 at 4:49 PM
smarteranalyst.com logoStock Update (NASDAQ:GILD): Gilead Sciences, Inc. Receives Around $22 Million To Support HIV Cure Research (NASDAQ:GILD)
www.smarteranalyst.com - January 10 at 4:49 PM
uk.finance.yahoo.com logoGilead Awards More Than $22 Million in Grants to Support HIV Cure Research (NASDAQ:GILD)
us.rd.yahoo.com - January 10 at 4:49 PM
us.rd.yahoo.com logoGilead Sciences: How Soon is Now? (NASDAQ:GILD)
us.rd.yahoo.com - January 10 at 4:49 PM
fool.com logoTop Biotech Resolutions for 2017 (NASDAQ:GILD)
us.rd.yahoo.com - January 10 at 4:49 PM
uk.finance.yahoo.com logoMOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod (NASDAQ:GILD)
us.rd.yahoo.com - January 10 at 4:49 PM
fool.com logoIs This the Solution to Gilead Sciences' Woes? (NASDAQ:GILD)
www.fool.com - January 10 at 9:20 AM
News IconNext Weeks Broker Price Targets For Gilead Sciences, Inc. (NASDAQ:GILD) (NASDAQ:GILD)
thecelebritytruth.com - January 10 at 2:02 AM
fool.com logo4 Things Gilead Sciences' CEO Says to Expect in 2017 (NASDAQ:GILD)
www.fool.com - January 9 at 6:13 PM
News IconThe Gilead Sciences, Inc. (GILD) Stock Rating Reaffirm by the Cowen and Company (NASDAQ:GILD)
news.xfoor.com - January 9 at 4:00 PM
thestreet.com logoThe Monday Sights, Sounds and Biotech Buzz from the J.P. Morgan Healthcare Conference (NASDAQ:GILD)
www.thestreet.com - January 9 at 4:00 PM

Social

Gilead Sciences (NASDAQ:GILD) Chart for Thursday, January, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Earnings History Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History Chart

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Last Updated on 1/19/2017 by MarketBeat.com Staff